



MARCH AGENDA


- February Recap
- New Item Request Submission Portal
- Lung Pacer – Missy Kukiela & Dr. Cherry
- E-Coin - Dr. El-Zawahry
- Altavia – Dr. El-Zawahry
- April Requests for Review





NEW ITEM REQUEST SUBMISSION PORTAL

SUPPLY CHAIN MANAGEMENT




LUNG PACER AEROPACE SYSTEM

CLINICAL CHAMPION(S): MISSY KUKIELA; DR. CHERRY

VENDOR: AEROPACE

THE REQUEST: PERMANENT USE AT UTMC

CRITICAL CARE VENTILATION & DIAPHRAGM SUPPORT





WHAT IS AEROPACE?

- Neurostimulation system for mechanical ventilation.
- Utilizes a triple lumen (cross functional) catheter inserted through the left IJ or subclavian access to stimulate diaphragm muscles via the phrenic nerve.
- Maps ventilation through a single console to provide two 12-minute therapies per day until liberation from mechanical ventilation.
- FDA approval: 12-2-2024



SUPPORTING CLINICAL DATA

Randomized Control Trials (Global)

- Rescue 2 and Rescue 3 studies conducted between 2017-2020 with emergency use granted during the Pandemic.

Control Trial Results:

- Reduction to VLOS approx.: 3.2 days
- Reduction to ICU LOS approx.: 3.4 days
- Overall reduction in reintubation and mortality approx.: 50%



POTENTIAL IMPACT

Aug 2025-Jan 2026

- VLOS \geq 5days: **67**
- Trach to vent: **35**
- Tracheotomy during stay: **10**

Assumptions based on 100% efficacy

- 10 tracheotomies avoided
- Potential liberation for 35 chronic patients



IMPACT TO CLINICIAN TIME

- Initial catheter placement-
- Zero net procedure time differential for provider (already placing triple lumen catheters)
- Two 12-minute treatments per day to RT treatment load (one per shift- includes mapping).
- One machine can be mobilized for several patients (current practice with Volara, cough assist, CPT).

PURCHASE OPTIONS

<u>Placement</u>	<u>Lease</u>	<u>Capital Purchase</u>
<ul style="list-style-type: none">▪ Capital: \$0.00▪ Disposables: \$7,998/per patient▪ Warranty: included▪ Service: included post warranty▪ No minimum usage requirements	<ul style="list-style-type: none">▪ Capital: \$3,000/month (zero-dollar buyout)▪ Term: 36 Months▪ Disposables: \$6,998/per patient▪ Service/Warranty: Included during lease term	<ul style="list-style-type: none">▪ Capital: \$80,000.00▪ Disposables: \$6,998/per patient▪ Warranty: 1 year included▪ Service: \$6,000/annually post warranty period

- Does **NOT** Connect to Wi-Fi, the Cloud, EMRs, or any other external network
- Does **NOT** require a software subscription, or software installations
- Does **NOT** store or transmit PHI/PII or similar and does not use any form of AI


ESTIMATED PROGRAM ROI (SIX MONTHS)

Category	Calculation Logic	Financial Impact
Total Technology Cost	67 patients x \$7,998	(\$535,866)
NTAP Reimbursement (Temp)	34 Medicare Patients(50%) x \$5,198.70	\$176,756
ICU Room Savings	52 Successes(77%) x 3.36 Days(1.05) x \$3,417	\$597,011
Ventilator Savings	52 Successes(77%) x 3.2 Days x \$1,201	\$199,846
Net Program ROI	(Savings + NTAP) – Total Tech Cost	\$437,747

Assumptions:

- 77% success rate (Pivotal clinical data); 3.2 day reduction in MV
- Medicare patients are estimated at 50%
- \$3,417 daily ICU rate (Vendor provided national estimate)
- \$1,201 daily ICU rate for additional vent related costs (Vendor provided national estimate)
- For every 1.0 day saved on a ventilator, the patient spends an additional .05 days in the ICU (Vendor provided national estimate)
- Capping reimbursement at 65% of our actual invoice price \$5,198.70 rather than the national maximum cap of \$23,650.90

Data: Aug 2025 – January 2026
 # of applicable UTMC Patients: 67



ECOIN - TIBIAL NEUROMODULATION SYSTEM
ALTAVIVA - TIBIAL NEUROMODULATION SYSTEM

CLINICAL CHAMPION: DR. EL-ZAWAHRY


VENDOR: ECOIN - VALENCIA/BOSTON SCIENTIFIC
ALTAVIVA – MEDTRONIC

THE REQUEST: TRIAL APPROVAL FOR BOTH PRODUCTS

ANKLE BASED (iTNS) VS SACRAL-BASED (SNS)

OAB NEUROMODULATION: iTNS VS. SNS COMPARATIVE VENN DIAGRAM

COMPARING ANKLE-BASED IMPLANTABLE TIBIAL NERVE STIMULATION TO SACRAL-BASED SACRAL NERVE STIMULATION TECHNIQUES FOR OVERACTIVE BLADDER (OAB)



PRODUCT OVERVIEW




PRODUCT OVERVIEW



SUPPLY CHAIN INFORMATION

PRODUCT SEGMENT: IMPLANTS - NEUROSTIMULATION



MULTI-VENDOR SPACE



3.2 MILLION SPEND (ANNUAL)




NO CONTRACT BREACH RISKS

CASE SUMMARY

Procedure Group: Neurostimulator Procedures, Urology, Open

Data Pull (February/2025 – January/2026)

Row Labels	Sum of Volume (All Cases)
EL-ZAWAHRY, AHMED	12
GERKEN, SARAH	1
UBEROI, RAVINDERA	1
(blank)	
Grand Total	14



CURRENT PRACTICE – SACRAL BASED

InterStim X Neurostimulator



- ▶ Part# 97800
- ▶ Vendor: Medtronic
- ▶ GTIN: 00763000484668
- ▶ FDA Approval Date: 2-22-2022
- ▶ Two Separate Sessions

Axonics F15 Neurostimulator



- ▶ Part# 4101
- ▶ Vendor: Axonics Modulation Tech
- ▶ GTIN: 00850022026135
- ▶ FDA Approval Date: 3-7-2022
- ▶ Two Separate Sessions



SACRAL PROCEDURAL COST IMPACT

InterStim X Sacral Neuromodulation System

- Pick Ticket (Avg): \$339.22
- Implant: \$12,452.00
- Total Supply Cost \$ 12,791.22
- Medicare Reimbursement: \$18,339.81
- Contribution Margin/Per Case: \$5,548.59


Axonics F15 Neurostimulation System

- Pick Ticket (Avg): \$339.22
- Implant: \$14,985.00
- Total Supply Cost: \$15,324.22
- Medicare Reimbursement: \$18,339.81
- Contribution Margin/Per Case: \$3,015.59

ALTERNATIVE PRACTICE-TIBIAL BASED

eCoin - Tibial Neuromodulation System


Altaviva - Tibial Neuromodulation System



- Part# EC-001
- Vendor: Valencia/Boston Scientific
- GTIN: 00850022357024
- FDA Approval Date: 3-1-2022

- Part# P7850N
- Vendor: Medtronic
- GTIN: 00763000494432
- FDA Approval Date: 9-18-2025

Implantable Tibial Nerve Stimulation (iTNS) Product Landscape





TIBIAL PROCEDURAL COST IMPACT

eCoin -Tibial Neuromodulation System

- Pick Ticket (Avg): \$339.22
- Implant: \$15,900
- Total Supply Cost \$16,239.22
- Medicare Reimbursement: \$18,339.81
- Contribution Margin/Per Case: \$2,100.59

Altaviva -Tibial Neuromodulation System


- Pick Ticket (Avg): \$339.22
- Implant: \$17,000
- Total Supply Cost: \$17,339.22
- Medicare Reimbursement: \$18,339.81
- Contribution Margin/Per Case: \$1,000.59

ESTIMATED REIMBURSEMENT

CPT 0816T – Open insertion or replacement of integrated neurostimulation system

- MEDICARE/MEDICAREADV. = **\$18,339.81**
- OH MEDICAID/MEDICAID ADV. = Do not know EAPG
- AETNA COMMERCIAL = **\$1,406.00**
- ANTHEM HMO/PPO = **\$2,969.00**
- MEDICAL MUTUAL OF OHIO = **\$29,981.24**
- UNITED HEALTHCARE = **\$5,619.00**
- OH BUREAU OF WORKERS COMP. = **\$27,454.70**

Payer Type	Patient Payer
Commercial	2
Medicaid	2
Medicare	10
Grand Total	14





APRIL REQUESTS FOR REVIEW

SUBMISSIONS APPROVED FOR APRIL REVIEW:

- TBD